
Joint CDA/NCID Guidances
JOINT CDA/NCID GUIDANCE FOR CLINICAL MANAGEMENT OF MPOX FOR HEALTHCARE PROFESSIONALS
DISEASE BACKGROUND AND OUTBREAK CHARACTERISTICS
Mpox is a zoonotic disease caused by the monkeypox virus (MPXV), a member of the Orthopoxvirus genus in the Poxviridae family which also includes cowpox, horsepox, smallpox (variola), and vaccinia viruses. MPXV is endemic in parts of Central and West Africa, where two distinct clades of MPXV, clade I (formerly Congo Basin clade) and clade II (formerly West African Clade), circulate in different geographical regions.
GLOBAL SITUATION
The World Health Organization (WHO) declared the second Public Health Emergency of International Concern (PHEIC) declaration for mpox on 14 August 2024 due to an upsurge of mpox in the Democratic Republic of the Congo (DRC) and a growing number of countries in Africa.
As of 27 September 2026, human infections with four distinct MPXV clades (Ia, Ib, IIa, and IIb) have been reported in at least 37 countries across Central, East, and West Africa, with a total of 71,368 laboratory-confirmed mpox cases and 296 laboratory-confirmed deaths (Case Fatality Ratio, CFR: 0.4%) reported. The DRC accounted for the majority (55%) of laboratory confirmed mpox cases since the start of the outbreak in 2024, with Uganda reporting the second-highest number of cases.
As of 26 August 2026, at least 142 cases of MPXV clade I have been reported across at least 43 countries outside Africa. Most reported infections have been clade Ib, although clade Ia and recombinant clade Ib/IIb infections have also been detected. While initial cases reported outside Africa were predominantly travel-associated, transmission patterns have since evolved, with cases increasingly linked to travel outside Central and Eastern Africa and community transmission of clade Ib documented in several countries, including within sexual networks. Recent travel associated clade I cases have been almost exclusively attributed to clade Ib and associated with relatively mild illness, with no deaths reported.
No cases of MPXV clade IIa have been reported outside Africa, while clade IIb, continues to circulate globally, driven primarily by sexual transmission in high-risk groups including men who have sex with men (MSM).
On 5 September 2025, the WHO ended the second PHEIC for mpox following a sustained decline in cases and deaths, improved understanding of transmission and severity risk factors, and increased response capacity in affected countries. Similarly, Africa CDC lifted mpox’s Public Health Emergency of Continental Security (PHECS) status on 22 January 2026. As of 27 September 2026, clades Ia/IIa remain limited to endemic areas in Africa, with limited cases reported outside of Africa, including recombinant clade Ib/IIb mpox cases.
Since February 2026, WHO had shifted to a population-group-based risk assessment irrespective of clade, reflecting limited evidence of meaningful differences in transmission between clades. Updated epidemiological parameters also suggest that CFR differences between the main circulating clades have narrowed. According to WHO latest risk assessment of mpox on 24 August 2026, the global public health risk was moderate for individuals with multiple sexual partners and children in historically endemic areas, and low for all other individuals.
Please refer to the Joint CDA-NCID Guidance for Clinical Management of MPOX for Healthcare Professionals for more details on the clinical management of MPOX
